| TITLE: |
A Phase II Study of BAY 43-9006 (NCS 724772) in Stage IV Malignant Melanoma (IND 69,896) |
| IRB #: |
12448 |
| SITE: |
NYU Clinical Cancer Center |
| PI: |
Anna Pavlick, DO
|
| Contact: |
212-731-5401 or Elizabeth.hardin@nyumc.org
|
|
| TITLE: |
Medarex Trial: Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination W/ A Melanoma Peptide Vaccine, & Melanoma Vaccine Monotherapy in HLA-A*0201-Positive Pts W/ Previously Treated Unresectable Stage III Or IV Melanoma. |
| IRB #: |
04-125, 7729 |
| SITE: |
MSKCC, CUMC |
| PI: |
Dr. Jedd Wolchok, Dr. Howard Kaufman |
| Contact: |
212-639-6570, 212-342-0232 or gd2023@columbia.edu
|
|
| TITLE: |
Temozolomide Trial: Phase II Trial of Extended-Dosing Temozolomide in Patients with Melanoma . |
| IRB #: |
00-142 |
| SITE: |
MSKCC |
| PI: |
Dr Paul Chapman |
| Contact: |
212-639-5015
|
|
| TITLE: |
A Phase II Study of the Efficacy, Safety and Immunogenicity of ONCOVEX in Patients with Inoperable Malignant Melanoma. |
| IRB #: |
4664 |
| SITE: |
CUMC |
| PI: |
Dr. Howard Kaufman |
| Contact: |
212-342-0232 or gd2023@columbia.edu
|
|
| TITLE: |
Dendritic Cell Vaccine Trial: Immune Responses to Antigen-Bearing Dendritic Cells in Patients with Malignancy - A Phase I Trial in Melanoma |
| IRB #: |
98-098 |
| SITE: |
MSKCC |
| PI: |
Dr James Young |
| Contact: |
212 639-7989 |
|
| TITLE: |
Intra-lesional rF-B7.1 versus rF-TRICOM in the Treatment of Metastatic Melanoma. |
| IRB #: |
14535 |
| SITE: |
CUMC |
| PI: |
Dr. Howard Kaufman |
| Contact: |
212-342-0232 or gd2023@columbia.edu |
|
| TITLE: |
A Phase I Study of gp75 DNA Vaccine in Patients with AJCC Stg III and IV Melanoma. |
| IRB #: |
00-131 |
| SITE: |
MSKCC |
| PI: |
Dr. Jedd Wolchok |
| Contact: |
212-639-6570 |
|
| TITLE: |
Injection of AJCC Stage IIb, IIc, III and IV Melanoma patients with a Multi-Epitope Peptide Vaccine using GM-CSF DNA as an Adjuvant: A Pilot Trial to Assess Safety and Immunity. |
| IRB #: |
00-142 |
| SITE: |
MSKCC |
| PI: |
Dr. Perales |
| Contact: |
212-639-8682 |
|
| TITLE: |
Study of Peripheral Blood and/or Bone Marrow, Including Detections of Occult Metastases, in Patients with Melanoma. |
| IRB #: |
91-125 |
| SITE: |
MSKCC |
| PI: |
Dr. Daniel Coit |
| Contact: |
212-639-8411 |
|
| TITLE: |
The Effect of High-dose Interleukin-2 Therapy on Peripheral Blood CD4+CD25+ Regulatory Cells in Patients with Metastatic Cancer. |
| IRB #: |
14993 |
| SITE: |
CUMC |
| PI: |
Dr. Howard Kaufman |
| Contact: |
212-342-0232 or gd2023@columbia.edu |
|
| TITLE: |
Prime-boost Immunization of AJCC Stage IIb, IIc, III and IV Melanoma Patients with Plasmid DNA and Poxviruses Encoding Tyrosinase: A Phase I Trial to Assess Safety and Immune Response. |
| IRB #: |
Pending |
| SITE: |
MSKCC & CUMC |
| PI: |
Dr. Jedd Wolchok & Dr. Howard Kaufman (Co-PI) |
| Contact: |
212-639-6570 & 212-342-0232 |
|
| TITLE: |
A Phase II Trial of a Prime-boost Immunization Strategy with Plasmid DNA and Poxviruses Encoding Tyrosinase and Concurrent High-dose Interleukin-2 in AJCC Stage IV Malignant Melanoma Patients. |
| IRB #: |
Pending |
| SITE: |
CUMC & MSKCC |
| PI: |
Dr. Howard Kaufman & Dr. Jedd Wolchok (Co-PI) |
| Contact: |
212-342-0232 & 212-639-6570 |
|
| TITLE: |
Phase II Trial of R115777 in Patients with Metastatic Melanoma. |
| IRB #: |
03-141 |
| SITE: |
MSKCC |
| PI: |
Dr. Paul Chapman |
| Contact: |
212-639-5015 |
|
| TITLE: |
A Phase II Study of Maintenance Biotherapy with Interleukin-2 and Granulocyte-Macrophage Colony Stimulating Factor in Patients with Metastatic Melanoma with a Partial Response or Stable Disease after Systemic Therapy. |
| IRB #: |
04-027 |
| SITE: |
MSKCC |
| PI: |
Dr Paul Chapman |
| Contact: |
212-639-5015 |
|
| TITLE: |
Phase II trial of sequential high dose Interleukin-2 followed by temozolomide and GM-CSF in metastatic melanoma |
| IRB #: |
3484 |
| SITE: |
CUMC
|
| PI: |
Dr Howard Kaufman |
| Contact: |
212-342-0232 or gd2023@columbia.edu |
|
